Company / R&D Expense
Dianthus Therapeutics, Inc. /DE/ R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$145.6M
FY2025
5-year range
$29.4M / $145.6M
FY2021-FY2025
Trend
+343.5%
vs FY2024
Sector context
#106 of 210
Health Care
What the data says
R&D Expense changed +343% YoY in FY2025, a notable deviation from the 9-year average annual change of +86%.
Based on SEC 10-K filings.
$146M in FY2025 with a 5-year CAGR of +23.5%.
Improved from $33M to $146M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +70.5%
- 5-Year CAGR
- +23.5%
- 10-Year CAGR
- -
Sector benchmark
#106 of 210 in Health CareTop 50% of 210This company $145.6M Sector average $644.0M
▼
-77.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +23.5%, indicating consistent growth.
- In FY2025, r&d expense increased 343.5% year-over-year.
- Ranks #106 out of 210 companies in the Health Care sector.
- Lowest r&d expense in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $145.6M | +343.5% |
| FY2024 | $32.8M | +0.0% |
| FY2023 | $32.8M | +11.8% |
| FY2022 | $29.4M | -37.2% |
| FY2021 | $46.8M | -7.6% |
| FY2020 | $50.6M | -14.5% |
| FY2019 | $59.2M | +43.2% |
| FY2018 | $41.3M | +48.2% |
| FY2017 | $27.9M | +382.5% |
| FY2016 | $5.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026